A method for treating or preventing thrombosis using dabigatran etexylate or a salt thereof with improved efficacy over conventional warfarin therapy.
- 专利权人:
- BOEHRINGER INGELHEIM INTERNATIONAL GMBH
- 发明人:
- PAUL A. REILLY
- 申请号：
- BRPI0921353
- 公开号：
- BRPI0921353A2
- 申请日:
- 2009.11.10
- 申请国别(地区):
- BR
- 年份:
- 2015
- 代理人:
- 摘要：
- A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has no risk factors for major bleeding events, the method comprising administering to the patient a dosage of >；150 mg b.i.d. to 300 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof.
- 来源网站：
- 中国工程科技知识中心
相关发明人
相关专利
- a method for treating or preventing thrombosis using dabigatran etexylate or a salt thereof with improved efficacy over conventional warfarin therapy.
- Method for treating or preventing thrombosis using dabigatran etexylate or a salt thereof with improved safety profile compared to conventional warfarin therapy
- METHOD FOR TREATING OR PREVENTING THROMBOSIS USING >；150 MG TO 300 MG B.I.D. OF DABIGATRAN ETEXILATE OR A SALT THEREOF WITH IMPROVED EFFICACY OVER CONVENTIONAL WARFARIN THERAPY
- METHOD FOR TREATING OR PREVENTING THROMBOSIS USING 150 MG B.I.D. OF DABIGATRAN ETEXILATE OR A SALT THEREOF WITH IMPROVED EFFICACY OVER CONVENTIONAL WARFARIN THERAPY
- METHOD FOR TREATING OR PREVENTING THROMBOSIS USING DABIGATRAN ETEXILATE OR A SALT THEREOF WITH IMPROVED EFFICACY OVER CONVENTIONAL WARFARIN THERAPY
